$ATOS
ATOSSA THERAPEUTICS, INC. Stock $atos

$atos Overview Financials Valuation SEC Filings Company Website

2021 Q4 Form 10-K Financial Statement

#000143774922004614 Filed on February 28, 2022

Income Statement

Concept	2021 Q4	2021 Q1	2021
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$3.001M	$2.150M	$11.31M
YoY Change	60.49%	7.5%	41.39%
% of Gross Profit
Research & Development	$1.827M	$1.379M	$9.210M
YoY Change	-22.6%	46.92%	39.38%
% of Gross Profit
Depreciation & Amortization	$1.730K	$9.000K	$23.00K
YoY Change	-82.7%	-26.98%	-51.06%
% of Gross Profit
Operating Expenses	$4.828M	$3.531M	$20.52M
YoY Change	14.13%	20.22%	40.49%
Operating Profit		-$3.531M	-$20.52M
YoY Change		20.22%	40.49%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net	-$3.630K	-$7.000K	-$85.00K
YoY Change	-99.89%	-32.76%	-266.67%
Pretax Income	-$4.832M	-$3.538M	-$20.61M
YoY Change	-35.41%	20.04%	15.58%
Income Tax	$0.00	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$4.832M	-$3.538M	-$20.61M
YoY Change	-35.41%	20.04%	15.58%
Net Earnings / Revenue
Basic Earnings Per Share		-$0.04	-$0.18
Diluted Earnings Per Share	-$38.12K	-$38.23K	-$176.2K
COMMON SHARES
Basic Shares Outstanding	126.6M	92.59M	117.0M
Diluted Shares Outstanding

Balance Sheet

Concept	2021 Q4	2021 Q1	2021
SHORT-TERM ASSETS
Cash & Short-Term Investments	$136.4M	$137.6M	$136.4M
YoY Change	244.39%	1363.83%	244.82%
Cash & Equivalents	$136.4M	$137.6M	$136.4M
Short-Term Investments
Other Short-Term Assets	$1.193M	$77.24K	$3.791M
YoY Change	81.58%	-42.58%	46.94%
Inventory
Prepaid Expenses	$2.488M	$2.550M
Receivables
Other Receivables
Total Short-Term Assets	$141.2M	$141.0M	$141.2M
YoY Change	230.23%	1108.79%	230.23%
LONG-TERM ASSETS
Property, Plant & Equipment	$20.00K	$15.84K	$20.00K
YoY Change	-4.76%	-46.74%	-50.0%
Goodwill
YoY Change
Intangibles	$54.00K
YoY Change	31.71%
Long-Term Investments
YoY Change
Other Assets	$22.00K	$16.47K	$2.000K
YoY Change	29.41%	-4.36%	-90.0%
Total Long-Term Assets	$22.00K	$49.23K	$22.00K
YoY Change	-68.12%	-66.09%	-68.57%
TOTAL ASSETS
Total Short-Term Assets	$141.2M	$141.0M	$141.2M
Total Long-Term Assets	$22.00K	$49.23K	$22.00K
Total Assets	$141.3M	$141.1M	$141.3M
YoY Change	229.75%	1094.35%	229.74%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.717M	$722.3K	$1.717M
YoY Change	8.06%	102.74%	7.99%
Accrued Expenses	$204.0K	$151.2K	$1.388M
YoY Change	119.35%	188.06%	28.52%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$3.126M	$1.379M	$3.126M
YoY Change	-80.05%	51.9%	-80.05%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities	$0.00	$0.00	$0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$3.126M	$1.379M	$3.126M
Total Long-Term Liabilities	$0.00	$0.00	$0.00
Total Liabilities	$3.126M	$1.400M	$3.126M
YoY Change	-80.05%	52.84%	-80.05%
SHAREHOLDERS EQUITY
Retained Earnings	-$129.2M	-$108.6M
YoY Change	15.49%	11.97%
Common Stock	$266.8M	$251.2M
YoY Change	92.7%	134.28%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$138.1M	$139.7M	$138.1M
YoY Change
Total Liabilities & Shareholders Equity	$141.3M	$141.1M	$141.3M
YoY Change	229.75%	1094.35%	229.74%

Cashflow Statement

Concept	2021 Q4	2021 Q1	2021
OPERATING ACTIVITIES
Net Income	-$4.832M	-$3.538M	-$20.61M
YoY Change	-35.41%	20.04%	15.58%
Depreciation, Depletion And Amortization	$1.730K	$9.000K	$23.00K
YoY Change	-82.7%	-26.98%	-51.06%
Cash From Operating Activities	-$3.665M	-$4.408M	-$16.47M
YoY Change	6.86%	36.47%	42.37%
INVESTING ACTIVITIES
Capital Expenditures	$400.00	$0.00	$9.000K
YoY Change			0.0%
Acquisitions
YoY Change
Other Investing Activities		$0.00
YoY Change
Cash From Investing Activities	$400.00	$0.00	-$9.000K
YoY Change			0.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	720.0	$102.4M	$113.3M
YoY Change	-100.0%		193.9%
NET CHANGE
Cash From Operating Activities	-3.665M	-$4.408M	-$16.47M
Cash From Investing Activities	400.0	$0.00	-$9.000K
Cash From Financing Activities	720.0	$102.4M	$113.3M
Net Change In Cash	-3.664M	$98.02M	$96.82M
YoY Change	-112.03%	-3134.68%	258.96%
FREE CASH FLOW
Cash From Operating Activities	-$3.665M	-$4.408M	-$16.47M
Capital Expenditures	$400.00	$0.00	$9.000K
Free Cash Flow	-$3.666M	-$4.408M	-$16.48M
YoY Change	6.87%		42.34%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2021	dei	Auditor Firm AuditorFirmId	243
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2020Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2020Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000
CY2020Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	1000
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	1000
CY2020Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	1000
CY2020Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	1000
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.18
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.18
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	175000000
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	175000000
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	126624000
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	126624000
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	47550000
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	47550000
CY2020	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	475000	USD
CY2020	atos	Issuance Of Common Stock And Warrants Issuance Costs IssuanceOfCommonStockAndWarrantsIssuanceCosts	1890000	USD
CY2020	atos	Issuance Of Preferred Stock And Warrants Issuance Costs IssuanceOfPreferredStockAndWarrantsIssuanceCosts	260000	USD
CY2021	atos	Issuance Of Common Stock And Warrants Issuance Costs IssuanceOfCommonStockAndWarrantsIssuanceCosts	5493000	USD
CY2020	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0	USD
CY2021	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	0	USD
CY2021Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	0	USD
CY2020Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	110000	USD
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2021Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0	USD
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	0	USD
CY2021Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	0	USD
CY2020Q2	atos	Increase Decrease In Operating Lease Right Of Use Asset IncreaseDecreaseInOperatingLeaseRightOfUseAsset	20000	USD
CY2020Q2	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	20000	USD
CY2021	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	699000
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	160000
CY2021Q2	atos	Payment For Negotiation Rights Negotiation Term PaymentForNegotiationRightsNegotiationTerm	P6M
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	136377000	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	39554000	USD
CY2021Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	110000	USD
CY2020Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	110000	USD
CY2021Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	2488000	USD
CY2020Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	1814000	USD
CY2021Q4	atos	Research And Development Tax Rebate Receivable ResearchAndDevelopmentTaxRebateReceivable	1072000	USD
CY2020Q4	atos	Research And Development Tax Rebate Receivable ResearchAndDevelopmentTaxRebateReceivable	635000	USD
CY2021Q4	us-gaap	Other Assets Current OtherAssetsCurrent	1193000	USD
CY2020Q4	us-gaap	Other Assets Current OtherAssetsCurrent	657000	USD
CY2021Q4	us-gaap	Assets Current AssetsCurrent	141240000	USD
CY2020Q4	us-gaap	Assets Current AssetsCurrent	42770000	USD
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	20000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	21000	USD
CY2021Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	0	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	13000	USD
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	0	USD
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	18000	USD
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	2000	USD
CY2020Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	17000	USD
CY2021Q4	us-gaap	Assets Assets	141262000	USD
CY2020Q4	us-gaap	Assets Assets	42839000	USD
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1717000	USD
CY2020Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1589000	USD
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	204000	USD
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	93000	USD
CY2021Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1184000	USD
CY2020Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	964000	USD
CY2021Q4	atos	Common Stock Warrant Lability CommonStockWarrantLability	0	USD
CY2020Q4	atos	Common Stock Warrant Lability CommonStockWarrantLability	13003000	USD
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	0	USD
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	18000	USD
CY2021Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	21000	USD
CY2020Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	4000	USD
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	3126000	USD
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	15671000	USD
CY2021Q4	us-gaap	Liabilities Liabilities	3126000	USD
CY2020Q4	us-gaap	Liabilities Liabilities	15671000	USD
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2020Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	22792000	USD
CY2020Q4	us-gaap	Common Stock Value CommonStockValue	8559000	USD
CY2021Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	243996000	USD
CY2020Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	129887000	USD
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-129234000	USD
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-111899000	USD
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	138136000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	27168000	USD
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	141262000	USD
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	42839000	USD
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	9210000	USD
CY2020	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	6608000	USD
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	11311000	USD
CY2020	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	7999000	USD
CY2021	us-gaap	Operating Expenses OperatingExpenses	20521000	USD
CY2020	us-gaap	Operating Expenses OperatingExpenses	14607000	USD
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-20521000	USD
CY2020	us-gaap	Operating Income Loss OperatingIncomeLoss	-14607000	USD
CY2021	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-0	USD
CY2020	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	2333000	USD
CY2021	atos	Warrant Financing Expense WarrantFinancingExpense	-0	USD
CY2020	atos	Warrant Financing Expense WarrantFinancingExpense	939000	USD
CY2021	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-85000	USD
CY2020	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	51000	USD
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-20606000	USD
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-17828000	USD
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-20606000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-17828000	USD
CY2021	atos	Preferred Stock Deemed Dividend PreferredStockDeemedDividend	-0	USD
CY2020	atos	Preferred Stock Deemed Dividend PreferredStockDeemedDividend	4503000	USD
CY2021	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-20606000	USD
CY2020	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-22331000	USD
CY2021	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.18
CY2020	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.97
CY2021	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	116950
CY2020	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	11309
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	13156000	USD
CY2020	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	4665000	USD
CY2020	atos	Common Stock And Warrants Issued During Period Value New Issues CommonStockAndWarrantsIssuedDuringPeriodValueNewIssues	29675000	USD
CY2020	atos	Adjustments To Additional Paid In Capital Allocation Of Common Stock Proceeds To Warrant Liability AdjustmentsToAdditionalPaidInCapitalAllocationOfCommonStockProceedsToWarrantLiability	8196000	USD
CY2020	atos	Preferred Stock And Warrants Issued During Period Value New Issues PreferredStockAndWarrantsIssuedDuringPeriodValueNewIssues	5165000	USD
CY2020	atos	Adjustments To Additional Paid In Capital Allocation Of Convertible Preferred Stock To Beneficial Conversion Feature And Warrant Liability AdjustmentsToAdditionalPaidInCapitalAllocationOfConvertiblePreferredStockToBeneficialConversionFeatureAndWarrantLiability	-2474000	USD
CY2020	atos	Adjustments To Additional Paid In Capital Preferred Stock Deemed Dividend AdjustmentsToAdditionalPaidInCapitalPreferredStockDeemedDividend	0	USD
CY2020	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	0	USD
CY2020	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	542000	USD
CY2020	atos	Stock Repurchased During Period For Stock Option Exercise And Taxes Value StockRepurchasedDuringPeriodForStockOptionExerciseAndTaxesValue	-556000	USD
CY2020	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	3019000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-17828000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	27168000	USD
CY2021	atos	Common Stock And Warrants Issued During Period Value New Issues CommonStockAndWarrantsIssuedDuringPeriodValueNewIssues	69668000	USD
CY2021	atos	Stock Issued During Period Value Warrant Exercised StockIssuedDuringPeriodValueWarrantExercised	43818000	USD
CY2021	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	1724000	USD
CY2021	atos	Stock Repurchased During Period For Stock Option Exercise And Taxes Value StockRepurchasedDuringPeriodForStockOptionExerciseAndTaxesValue	-1906000	USD
CY2021	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	5267000	USD
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-20606000	USD
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	138136000	USD
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-20606000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-17828000	USD
CY2021	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	5267000	USD
CY2020	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	3019000	USD
CY2021	us-gaap	Disposal Group Not Discontinued Operation Gain Loss On Disposal DisposalGroupNotDiscontinuedOperationGainLossOnDisposal	-0	USD
CY2020	us-gaap	Disposal Group Not Discontinued Operation Gain Loss On Disposal DisposalGroupNotDiscontinuedOperationGainLossOnDisposal	-32000	USD
CY2021	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	23000	USD
CY2020	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	47000	USD
CY2021	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	0	USD
CY2020	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	2333000	USD
CY2021	atos	Warrant Financing Expense WarrantFinancingExpense	0	USD
CY2020	atos	Warrant Financing Expense WarrantFinancingExpense	939000	USD
CY2021	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	674000	USD
CY2020	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	952000	USD
CY2021	atos	Increase Decrease In Research And Development Tax Rebate Receivable IncreaseDecreaseInResearchAndDevelopmentTaxRebateReceivable	437000	USD
CY2020	atos	Increase Decrease In Research And Development Tax Rebate Receivable IncreaseDecreaseInResearchAndDevelopmentTaxRebateReceivable	-105000	USD
CY2021	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	521000	USD
CY2020	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	631000	USD
CY2021	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	128000	USD
CY2020	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1295000	USD
CY2021	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	111000	USD
CY2020	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	15000	USD
CY2021	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	220000	USD
CY2020	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	64000	USD
CY2021	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	17000	USD
CY2020	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	-8000	USD
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-16472000	USD
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-11570000	USD
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	9000	USD
CY2020	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	9000	USD
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-9000	USD
CY2020	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-9000	USD
CY2021	atos	Proceeds From Issuance Of Common Stock Net Of Issuance Costs ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts	0	USD
CY2020	atos	Proceeds From Issuance Of Common Stock Net Of Issuance Costs ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts	4665000	USD
CY2021	atos	Proceeds From Issuance Of Common Stock And Warrants Net Of Issuance Costs ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCosts	69668000	USD
CY2020	atos	Proceeds From Issuance Of Common Stock And Warrants Net Of Issuance Costs ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCosts	28954000	USD
CY2021	us-gaap	Proceeds From Issuance Of Preferred Stock Preference Stock And Warrants ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants	0	USD
CY2020	us-gaap	Proceeds From Issuance Of Preferred Stock Preference Stock And Warrants ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants	4947000	USD
CY2021	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	391000	USD
CY2020	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	0	USD
CY2021	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	573000	USD
CY2020	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	14000	USD
CY2021	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	43818000	USD
CY2020	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	0	USD
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	113304000	USD
CY2020	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	38552000	USD
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	96823000	USD
CY2020	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	26973000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	39664000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	12691000	USD
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	136487000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	39664000	USD
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	136377000	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	39554000	USD
CY2021Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	110000	USD
CY2020Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	110000	USD
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	136487000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	39664000	USD
CY2021	atos	Reclassification Of Warrant Liability To Equity ReclassificationOfWarrantLiabilityToEquity	13003000	USD
CY2020	atos	Reclassification Of Warrant Liability To Equity ReclassificationOfWarrantLiabilityToEquity	0	USD
CY2021	us-gaap	Stock Issued1 StockIssued1	1333000	USD
CY2020	us-gaap	Stock Issued1 StockIssued1	541000	USD
CY2021	atos	Allocation Of Proceeds To Warrant Liability AllocationOfProceedsToWarrantLiability	0	USD
CY2020	atos	Allocation Of Proceeds To Warrant Liability AllocationOfProceedsToWarrantLiability	4503000	USD
CY2021	us-gaap	Nature Of Operations NatureOfOperations	<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:justify;"><b><a href="#" id="notes" title="notes"/>NOTE <em style="font: inherit;">1:</em> NATURE OF OPERATIONS</b></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:7.2pt;margin-top:0pt;text-align:left;text-indent:72pt;"> </p> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt 14.4pt 0pt 5.2pt; text-align: left; text-indent: 54pt;">On <em style="font: inherit;"> January 6, 2020, </em>we changed our corporate name from Atossa Genetics Inc. to Atossa Therapeutics, Inc. Atossa Therapeutics, Inc. (the Company) was incorporated on <em style="font: inherit;"> April 30, 2009, </em>in the State of Delaware. The Company was initially formed to develop and market medical devices, laboratory tests and therapeutics to address breast health conditions. The Company is currently focused on development of its pharmaceuticals for the treatment of the novel coronavirus (COVID-<em style="font: inherit;">19</em>), breast cancer and other breast conditions. The Company’s fiscal year ends on <em style="font: inherit;"> December 31.</em></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:7.2pt;margin-right:14.4pt;margin-top:0pt;text-align:left;text-indent:54pt;"><i> </i></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:7.2pt;margin-right:14.4pt;margin-top:0pt;text-align:left;text-indent:54pt;"><i>Impact of the Novel Coronavirus </i></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:28.8pt;margin-right:14.4pt;margin-top:0pt;text-align:left;text-indent:28.8pt;"> </p> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 8pt; text-indent: 54pt;">The continued spread of the COVID-<em style="font: inherit;">19</em> pandemic is affecting the U.S. and global economies and <em style="font: inherit;"> may </em>affect the Company’s operations and those of <em style="font: inherit;">third</em> parties on which the Company relies, including causing possible disruptions in the supply of the Company’s Endoxifen, AT-<em style="font: inherit;">H201,</em> AT-<em style="font: inherit;">301</em> and the pace of enrollment in our clinical trials. In addition, the COVID-<em style="font: inherit;">19</em> pandemic <em style="font: inherit;"> may </em>affect the operations of the U.S. FDA and other health authorities including similar entities/agencies in Sweden and Australia, which could result in delays in meetings, reviews and approvals. Additionally, while the potential economic impact brought by, and the duration of, the COVID-<em style="font: inherit;">19</em> pandemic is difficult to assess or predict, the impact of the COVID-<em style="font: inherit;">19</em> pandemic on the global financial markets <em style="font: inherit;"> may </em>reduce the Company’s ability to access capital, which could negatively impact the Company’s short-term and long-term liquidity. The ultimate impact of the COVID-<em style="font: inherit;">19</em> pandemic is highly uncertain and subject to change. We do <em style="font: inherit;">not</em> yet know the full extent of potential delays or impacts on our business, financing or clinical trial activities or on healthcare systems or the global economy as a whole, however, we have <em style="font: inherit;">not</em> experienced a significant delay in the enrollment or the drug supply for our ongoing and planned clinical studies, including studies of Endoxifen, AT-<em style="font: inherit;">301</em> and AT-<em style="font: inherit;">H201.</em> In recent weeks the number of reported cases of COVID-<em style="font: inherit;">19</em> has declined in many countries. If this trend continues it <em style="font: inherit;"> may </em>be difficult to enroll participants in our COVID-<em style="font: inherit;">19</em> clinical studies.</p>
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-20606000	USD
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-16472000	USD
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	136377000	USD
CY2021Q4	atos	Working Capital Deficit WorkingCapitalDeficit	138114000	USD
CY2021	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	113486000	USD
CY2021	us-gaap	Use Of Estimates UseOfEstimates	<p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt 7.2pt; text-align: left; text-indent: 54pt;"><b>Use of Estimates:</b></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:36pt;"> </p> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt 7.2pt; text-align: left; text-indent: 54pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.</p> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt 7.2pt 0pt 5.2pt; text-align: left; text-indent: 36pt;"> </p>
CY2020Q4	atos	Common Stock Warrant Lability CommonStockWarrantLability	13003000	USD
CY2021Q1	atos	Common Stock Warrant Lability CommonStockWarrantLability		USD
CY2020Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	129887000	USD
CY2021Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	139619000	USD
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-111899000	USD
CY2021Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-108628000	USD
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	36000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	186000	USD
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	16000	USD
CY2020Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	165000	USD
CY2021	us-gaap	Depreciation Depreciation	10000	USD
CY2020	us-gaap	Depreciation Depreciation	19000	USD
CY2021	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0	USD
CY2020	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	0	USD
CY2021Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	54000	USD
CY2020Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	41000	USD
CY2021Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	13000	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	28000	USD
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	0	USD
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2021Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	110000	USD
CY2021Q4	atos	Research And Development Current ResearchAndDevelopmentCurrent	1853000	USD
CY2020Q4	atos	Research And Development Current ResearchAndDevelopmentCurrent	1216000	USD
CY2021Q4	us-gaap	Prepaid Insurance PrepaidInsurance	461000	USD
CY2020Q4	us-gaap	Prepaid Insurance PrepaidInsurance	418000	USD
CY2021Q4	atos	Professional Services Current ProfessionalServicesCurrent	124000	USD
CY2020Q4	atos	Professional Services Current ProfessionalServicesCurrent	128000	USD
CY2021Q4	us-gaap	Deposit Assets DepositAssets	14000	USD
CY2020Q4	us-gaap	Deposit Assets DepositAssets	14000	USD
CY2021Q4	us-gaap	Prepaid Rent PrepaidRent	5000	USD
CY2020Q4	us-gaap	Prepaid Rent PrepaidRent	5000	USD
CY2021Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	31000	USD
CY2020Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	33000	USD
CY2021Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	2488000	USD
CY2020Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	1814000	USD
CY2021Q4	us-gaap	Accrued Bonuses Current AccruedBonusesCurrent	894000	USD
CY2020Q4	us-gaap	Accrued Bonuses Current AccruedBonusesCurrent	690000	USD
CY2021Q4	us-gaap	Accrued Vacation Current AccruedVacationCurrent	183000	USD
CY2020Q4	us-gaap	Accrued Vacation Current AccruedVacationCurrent	171000	USD
CY2021Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	107000	USD
CY2020Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	103000	USD
CY2021Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1184000	USD
CY2020Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	964000	USD
CY2021Q4	atos	Number Of Shares Authorized To Issue NumberOfSharesAuthorizedToIssue	185000000
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	175000000
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.18
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2014Q2	atos	Stockholder Rights Agreement Number Of Preferred Stock Right Distributed For Each Share Of Common Stock StockholderRightsAgreementNumberOfPreferredStockRightDistributedForEachShareOfCommonStock	1
CY2014Q2	atos	Stockholder Rights Agreement Acquiring Person Percentage Of Ownership StockholderRightsAgreementAcquiringPersonPercentageOfOwnership	0.15	pure
CY2014Q2	atos	Stockholder Rights Agreement Acquiring Person Additional Percentage Of Ownership StockholderRightsAgreementAcquiringPersonAdditionalPercentageOfOwnership	0.020	pure
CY2014Q2	atos	Stockholder Rights Agreement Initial Exercise Price Of Each Right StockholderRightsAgreementInitialExercisePriceOfEachRight	15.00
CY2014Q2	atos	Stockholder Rights Agreement Share Price StockholderRightsAgreementSharePrice	30.00
CY2021Q4	atos	Consummate A Business Combination Percentage Of Acquired Outstanding Shares ConsummateABusinessCombinationPercentageOfAcquiredOutstandingShares	0.50	pure
CY2021Q4	atos	Consummate A Business Combination Percentage Of Aggregate Ordinary Voting Power ConsummateABusinessCombinationPercentageOfAggregateOrdinaryVotingPower	0.50	pure
CY2021Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	22277000
CY2021	atos	Class Of Warrant Or Right Exercised During Period ClassOfWarrantOrRightExercisedDuringPeriod	37451000
CY2021	atos	Stock Issued During Period Shares Warrant Exercised StockIssuedDuringPeriodSharesWarrantExercised	37451000
CY2020	atos	Class Of Warrant Or Right Exercised During Period ClassOfWarrantOrRightExercisedDuringPeriod	0
CY2021	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	43818000	USD
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-20606000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-17828000	USD
CY2021	atos	Preferred Stock Deemed Dividend PreferredStockDeemedDividend	-0	USD
CY2020	atos	Preferred Stock Deemed Dividend PreferredStockDeemedDividend	4503000	USD
CY2021	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-20606000	USD
CY2020	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-22331000	USD
CY2021	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	116950
CY2020	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	11309
CY2021	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.18
CY2020	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.97
CY2021	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-4327000	USD
CY2020	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-3744000	USD
CY2021	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	0	USD
CY2020	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	26000	USD
CY2021	us-gaap	Income Tax Reconciliation Nondeductible Expense Other IncomeTaxReconciliationNondeductibleExpenseOther	81000	USD
CY2020	us-gaap	Income Tax Reconciliation Nondeductible Expense Other IncomeTaxReconciliationNondeductibleExpenseOther	1082000	USD
CY2021	atos	Effective Income Tax Rate Reconciliation Other Deferred Items EffectiveIncomeTaxRateReconciliationOtherDeferredItems	-100000	USD
CY2020	atos	Effective Income Tax Rate Reconciliation Other Deferred Items EffectiveIncomeTaxRateReconciliationOtherDeferredItems	-350000	USD
CY2021	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	-557000	USD
CY2020	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	0	USD
CY2021	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	4903000	USD
CY2020	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	2986000	USD
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2021Q4	us-gaap	Deferred Tax Assets Inventory DeferredTaxAssetsInventory	0	USD
CY2020Q4	us-gaap	Deferred Tax Assets Inventory DeferredTaxAssetsInventory	22000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Compensated Absences DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences	38000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Compensated Absences DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences	36000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	3007000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	2408000	USD
CY2021Q4	atos	Deferred Tax Assets Lease Obligation DeferredTaxAssetsLeaseObligation	0	USD
CY2020Q4	atos	Deferred Tax Assets Lease Obligation DeferredTaxAssetsLeaseObligation	4000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	382000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	449000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	11511000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	7118000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	0	USD
CY2020Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	1000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	14937000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	10034000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	1000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	4000	USD
CY2021Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	1000	USD
CY2020Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	-0	USD
CY2021Q4	atos	Deferred Tax Liabilities Right Of Use Asset DeferredTaxLiabilitiesRightOfUseAsset	-0	USD
CY2020Q4	atos	Deferred Tax Liabilities Right Of Use Asset DeferredTaxLiabilitiesRightOfUseAsset	4000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	USD
CY2020Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	USD
CY2021Q4	atos	Gross Net Operating Loss Carryforwards GrossNetOperatingLossCarryforwards	52200000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	14937000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	10034000	USD
CY2021	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	4903000	USD
CY2020	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	2986000	USD
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	USD
CY2021Q4	us-gaap	Cash Uninsured Amount CashUninsuredAmount	136185	USD
CY2020Q4	us-gaap	Cash Uninsured Amount CashUninsuredAmount	39345	USD
CY2021	atos	Lessee Operating Lease Monthly Rent Payments LesseeOperatingLeaseMonthlyRentPayments	1000	USD
CY2021	us-gaap	Operating Lease Expense OperatingLeaseExpense	17000	USD
CY2020	us-gaap	Operating Lease Expense OperatingLeaseExpense	57000	USD
CY2021Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.113	pure
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	0	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	1000	USD
CY2021	us-gaap	Operating Lease Payments OperatingLeasePayments	19000	USD
CY2020	us-gaap	Operating Lease Payments OperatingLeasePayments	55000	USD
CY2021	us-gaap	Short Term Lease Cost ShortTermLeaseCost	26000	USD
CY2020	us-gaap	Short Term Lease Cost ShortTermLeaseCost	18000	USD
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	5267000	USD
CY2020	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3019000	USD
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	7067000
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	2.74
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	3819000
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	2.98
CY2021	atos	Sharebased Compensation Arrangement By Sharebased Payment Award Options Grants In Period Intrinsic Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue	100000	USD
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	2.46
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	2754000	USD
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	4.56
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	-0
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	0
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	10027000
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	2.82
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y3M7D
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	1006000	USD
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	6472000
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	2.87
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P7Y9M10D
CY2021Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	938000	USD
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	10027000
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	2.82
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P8Y3M7D
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	1006000	USD
CY2021Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares	3555000
CY2021Q2	atos	Payment For Negotiation Rights PaymentForNegotiationRights	1000000	USD

Files In Submission

Name	View Source	Status
0001437749-22-004614-index-headers.html	Edgar Link	pending
0001437749-22-004614-index.html	Edgar Link	pending
0001437749-22-004614.txt	Edgar Link	pending
0001437749-22-004614-xbrl.zip	Edgar Link	pending
atos-20211231.xsd	Edgar Link	pending
atos-20211231_cal.xml	Edgar Link	unprocessable
atos-20211231_def.xml	Edgar Link	unprocessable
atos-20211231_lab.xml	Edgar Link	unprocessable
atos-20211231_pre.xml	Edgar Link	unprocessable
atos20211231_10k.htm	Edgar Link	pending
atos20211231_10k_htm.xml	Edgar Link	completed
ex_316489.htm	Edgar Link	pending
ex_316490.htm	Edgar Link	pending
ex_316491.htm	Edgar Link	pending
ex_316492.htm	Edgar Link	pending
ex_316493.htm	Edgar Link	pending
ex_316494.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ATOS
ATOSSA THERAPEUTICS, INC. Stock $atos

2021 Q4 Form 10-K Financial Statement

#000143774922004614 Filed on February 28, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ATOS ATOSSA THERAPEUTICS, INC. Stock $atos

2021 Q4 Form 10-K Financial Statement

#000143774922004614 Filed on February 28, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ATOS
ATOSSA THERAPEUTICS, INC. Stock $atos